The US Food and Drug Administration (FDA) has approved an improved stool collection kit of Geneoscopy’s RNA-based colorectal cancer (CRC) screening test, ColoSense.

The new kit enhances user convenience by eliminating the need for patients to separate their stool sample into various containers, while maintaining the test’s clinical performance and streamlining the at-home testing process.

ColoSense is designed for people aged 45 years and above who are at average CRC risk. The test employs advanced RNA technology to identify biomarkers for CRC and advanced adenomas (AA), which are precancerous lesions with the potential to develop into cancer if not treated.